My Legacy Advisors LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN)

My Legacy Advisors LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.0% in the 4th quarter, HoldingsChannel reports. The firm owned 3,065 shares of the medical research company’s stock after purchasing an additional 147 shares during the quarter. My Legacy Advisors LLC’s holdings in Amgen were worth $824,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. grew its stake in Amgen by 0.6% during the 4th quarter. Steigerwald Gordon & Koch Inc. now owns 70,450 shares of the medical research company’s stock worth $18,362,000 after purchasing an additional 434 shares in the last quarter. Liberty One Investment Management LLC grew its position in shares of Amgen by 9.3% during the fourth quarter. Liberty One Investment Management LLC now owns 14,895 shares of the medical research company’s stock worth $3,882,000 after buying an additional 1,264 shares in the last quarter. Kelly Financial Services LLC purchased a new stake in shares of Amgen during the fourth quarter worth approximately $3,784,000. HF Advisory Group LLC raised its holdings in Amgen by 7.8% in the fourth quarter. HF Advisory Group LLC now owns 2,113 shares of the medical research company’s stock valued at $551,000 after acquiring an additional 152 shares in the last quarter. Finally, IAM Advisory LLC lifted its stake in Amgen by 1.6% in the fourth quarter. IAM Advisory LLC now owns 7,128 shares of the medical research company’s stock worth $1,858,000 after acquiring an additional 109 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 1.0 %

AMGN opened at $272.11 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $146.27 billion, a price-to-earnings ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56. The business’s fifty day moving average is $273.95 and its two-hundred day moving average is $307.22. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period last year, the firm posted $4.96 EPS. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is 115.24%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AMGN shares. Royal Bank of Canada reduced their price objective on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft lowered their price objective on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. UBS Group cut their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. Finally, Truist Financial cut their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.